4-(2,2-dimethylpropyl)-2-methyl-1H-imidazole | 1022154-70-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(2,2-dimethylpropyl)-2-methyl-1H-imidazole
• 英文别名: 2-methyl-5-neopentyl-1H-imidazole；5-(2,2-dimethylpropyl)-2-methyl-1H-imidazole
• CAS: 1022154-70-6
• 化学式: C₉H₁₆N₂
• 分子量: 152.239
• InChiKey: TVYPSGOXQVFHTF-UHFFFAOYSA-N

物化性质

• 沸点：
  294.3±9.0 °C(Predicted)
• 密度：
  0.953±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-(2,2-dimethylpropyl)-2-methyl-1H-imidazole 在 正丁基锂 、 三乙胺 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity

  摘要：

  We report the development and characterization of compound 22 (MK-5046), a potent, selective small molecule agonist of BRS-3 (bombesin receptor subtype-3). In pharmacological testing using diet-induced obese mice, compound 22 caused mechanism-based, dose-dependent reductions in food intake and body weight.

  DOI：

  10.1021/ml100196d
• 作为产物：
  描述：

  4,4-二甲基-1-戊烯 在 盐酸 、 titanium(III) chloride 、 nitrosonium tetrafluoroborate 作用下， 以 甲醇 、 水 为溶剂， 反应 72.5h， 生成 4-(2,2-dimethylpropyl)-2-methyl-1H-imidazole
  参考文献：
  名称：

  Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity

  摘要：

  We report the development and characterization of compound 22 (MK-5046), a potent, selective small molecule agonist of BRS-3 (bombesin receptor subtype-3). In pharmacological testing using diet-induced obese mice, compound 22 caused mechanism-based, dose-dependent reductions in food intake and body weight.

  DOI：

  10.1021/ml100196d

文献信息

• Substituted inmidazoles as bombesin receptor subtype-3 modulators
  申请人：Chen David

  公开号：US20100022598A1

  公开（公告）日：2010-01-28

  Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

  某些新型取代咪唑是人类炸弹素受体的配体，特别是人类炸弹素受体亚型-3（BRS-3）的选择性配体。因此，它们对于治疗、控制或预防对BRS-3调节敏感的疾病和紊乱，如肥胖症和糖尿病，具有用处。
• Nicotinamide Derivatives
  申请人：Blake Tanisha D.

  公开号：US20080146569A1

  公开（公告）日：2008-06-19

  The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof, wherein the substituents are as defined herein, compositions containing such compounds and the uses of such compounds for the treatment of various diseases and conditions such as asthma.

  本发明涉及公式（I）的化合物及其药用可接受的盐和溶剂化合物，其中取代基如本文所定义，包含这种化合物的组合物以及这种化合物用于治疗各种疾病和状况，如哮喘。
• Methods and compositions of treating a flaviviridae family viral infection
  申请人：Einav Shirit

  公开号：US20100015093A1

  公开（公告）日：2010-01-21

  Briefly described, embodiments of this disclosure include compounds, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of inhibiting HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3′UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like.

  简要概述，本公开的实施例包括化合物、药物组合物、治疗感染黄病毒科病毒的宿主的方法、抑制宿主中HCV复制的方法、抑制NS4B多肽与HCV负链RNA的3′UTR结合的方法、治疗宿主肝纤维化的方法等。
• Substituted imidazole as bombesin receptor subtype-3 modulators
  申请人：Merck Sharp & Dohme Corp.

  公开号：US08193228B2

  公开（公告）日：2012-06-05

  Certain novel substituted imidazoles are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

  某些新型取代咪唑是人类炸弹素受体的配体，特别是人类炸弹素受体亚型-3（BRS-3）的选择性配体。因此，它们可用于治疗、控制或预防对BRS-3调节敏感的疾病和障碍，如肥胖症和糖尿病。
• SUBSTITUTED IMIDAZOLES AS BOMBESIN RECEPTOR SUBTYPE-3 MODULATORS
  申请人：Merck & Co., Inc.

  公开号：EP2091937A2

  公开（公告）日：2009-08-26